Author Topic: (ECTRIMS) MedDay's high-dose biotin (MD1003) improves disability in progressive MS  (Read 34 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8192
  • MS diagnosed 1980
  • Location: Pacific Northwest
About some research on biotin presented at the ECTRIMS conference in Paris this month (from Multiple Sclerosis News Today, October 26, 2017):

Quote
#MSParis2017 – MedDay’s High-Dose Biotin, MD1003, Improves Disability in Progressive MS Patients

 Magdalena Kegel

MD1003, a high-dose biotin developed by MedDay, slowed or prevented further disease progression among progressive multiple sclerosis (MS) patients in a Phase 3 clinical trial, researchers announced at the Oct. 25–28 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France.

The effects of the treatment were seen to be upheld over time and benefitted all patients in the trial similarly, offering hope to progressive MS patients that a new treatment for their condition may be on the horizon.

Presented by a team of researchers in France, the poster titled, “Effect of MD1003 (High-Dose Biotin) for the treatment of progressive MS: 36-month follow-up data,” highlighted robust effects of high-dose biotin over several years.


The MS-SPI Phase 3 trial (NCT02220933) included patients with progressive MS with no inflammatory disease activity. Patients were randomly assigned to treatment with 100 mg of MD1003 three times daily, or a placebo.

In total, 103 patients received MD1003 and 51 were on placebo treatment. Participants in the placebo group (42 patients) were switched to MD1003 after 12 months.

After nine months, 13% of MD1003-treated patients had improved their Expanded Disability Status Scale (EDSS) scores and performed better on the timed 25-foot walk, a measure of mobility and leg function. Meanwhile, none of the patients receiving a placebo had improved. This proportion remained stable over the next two years.

Researchers noted that while the change in EDSS was halted among placebo-treated patients when they switched to MD1003, they remained at a higher level throughout the study, suggesting that earlier treatment is advisable.

At 36 months, 67% of those who received MD1003 throughout the study had experienced an adverse event, compared to 79% of those who first received a placebo.

The team suggested that the effects of MD1003 appear sustainable over time, the drug is able to halt disease progression, and it is well-tolerated.

In a separate poster also presented at the meeting, “Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): subgroup analyses,” researchers demonstrated that the treatment’s effects were similar for people with primary or secondary progressive MS, or those with high or low EDSS scores in the MS-SPI Phase 3 trial.

The effects were independent of treatment with another disease-modifying drug and of intensive physical therapy.

Finally, the study, “MD1003 in progressive multiple sclerosis: 24-month brain MRI results of the MS-SPI trial,” presented by Douglas Arnold from McGill University Health Centre in Canada, discussed the pseudo-atrophy phenomenon.

Arnold showed that after 12 months, people treated with MD1003 had a lower whole brain and gray matter volume compared to those in the placebo group.

After 24 months, the MD1003 group appeared to have stabilized, while those who had been on placebo for the first 12 months experienced reduced volumes when switched to MD1003, an effect that was maintained in the following 12 months.

No difference in brain volume between the two groups could be detected at 24 months.

Researchers argue that this decrease is linked to a lowering of brain water volume, and may be the result of increased energy production triggered by high biotin doses.

Nonetheless, the results showed that brain energy metabolism is a key factor in progressive MS that can be targeted with high doses of biotin.

The article can be seen here.
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8192
  • MS diagnosed 1980
  • Location: Pacific Northwest
300mg/day biotin may be recommended for progressive MS
« Reply #1 on: November 11, 2017, 10:33:26 am »
Howard Weiner, MD, an authority on MS, seems to be recommending biotin according to this article in HealthLine Newsletter (May 12, 2017) though the way it is put is a bit unclear:

https://www.healthline.com/health-news/high-dose-biotin-for-multiple-sclerosis
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
1 Replies
96 Views
Last post April 27, 2016, 04:38:39 pm
by agate
0 Replies
54 Views
Last post February 04, 2017, 08:08:28 am
by agate
1 Replies
72 Views
Last post November 14, 2018, 04:04:14 pm
by agate
0 Replies
41 Views
Last post November 17, 2017, 09:19:07 pm
by agate
0 Replies
32 Views
Last post July 22, 2018, 05:07:19 pm
by agate